Skip to main content
Home / Current Computer - Aided Drug Design, Volume 4, Number 1

PET and SPECT Imaging of Tumor Biology: New Approaches Towards Oncology Drug Discovery and Development

Buy Article:

$68.00 + tax (Refund Policy)

Authors: Van Dort, Marcian E.; Rehemtulla, Alnawaz; Ross, Brian D.

Source: Current Computer - Aided Drug Design, Volume 4, Number 1, 2008, pp. 46-53(8)

Publisher: Bentham Science Publishers

Spiraling drug developmental costs and lengthy time-to-market introduction are two critical challenges facing the pharmaceutical industry. The clinical trials success rate for oncology drugs is reported to be 5% as compared to other therapeutic categories (11%) with most failures often encountered late in the clinical development process. PET and SPECT nuclear imaging technologies could play an important role in facilitating the drug development process improving the speed, efficiency and cost of drug development. This review will focus on recent studies of PET and SPECT radioligands in oncology and their application in the investigation of tumor biology. The use of clinically-validated radioligands as imaging-based biomarkers in oncology could significantly impact new cancer therapeutic development.





Keywords: PET; SPECT; drug development; radioligands; tumor biomarkers; tumor imaging

Document Type: Research Article

Publication date: 01 March 2008

More about this publication?
  • Current Computer-Aided Drug Design aims to publish all the latest developments in drug design based on computational techniques. The field of computer-aided drug design has had extensive impact in the area of drug design. Current Computer-Aided Drug Design is an essential journal for all medicinal chemists who wish to be kept informed and up-to-date with all the latest and important developments in computer-aided methodologies and their applications in drug discovery. Each issue contains a series of timely, in-depth reviews written by leaders in the field, covering a range of computational techniques for drug design, screening, ADME studies, etc., providing excellent rationales for drug development.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites

Share Content

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content